Latest Guidelines to Enhance Patient Recovery after Cardiac Surgery Strongly Recommend: Maintenance of Chest Tube Patency to Prevent Complications OMAHA, Neb.–(BUSINESS WIRE)–Centese, Inc. today announced completion of the first clinical study of its Thoraguard® digital drainage system used in cardiac surgery at Stanford University Medical Center. Thoraguard is the first surgical […]
Author: Ken Dropiewski
ASNC AND ASE ANNOUNCE 2020 QCDR DESIGNATION FOR THE IMAGEGUIDE REGISTRY
For ImageGuide Users, ASNC and ASE members, QCDR Status Eases MIPS Reporting Burden Fairfax, VA (January 21, 2020) – The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) are pleased to announce that the Centers for Medicare and Medicaid Services have approved the ImageGuide Registry® […]
Novoheart Contracts with Global Pharma to Develop Novel Microplate for High Throughput Drug Screening Using Engineered Human Heart Tissue Strips
New 96-Well Microplates (hvCTS-96) to Further Advance MyHeart™ Platform Capabilities for High-throughput Screening of Compounds on Engineered Human Heart Tissue Strips Novoheart Partners with a Global Pharma to Design and Develop the New Microplate and Will Retain Full Ownership of All IP Novoheart is to Enter a Billion-dollar Market and Generate […]
Additional Ventures Launches Comprehensive Initiative Focused on Innovation in Single Ventricle Heart Defect Research
$5.7 million was awarded to five research institutions as they set out with the goal of accelerating scientific discoveries and development of treatments for single ventricle heart defects PALO ALTO, Calif., Jan. 21, 2020 /PRNewswire/ — Additional Ventures announced the recipients of five “Innovation Funds” today as part of a large-scale coordinated research effort […]
Venus Medtech Announces the Addition of Two Cardiovascular Experts to Their Advisory Team
HANGZHOU, China, Jan. 20, 2020 /PRNewswire/ — The leading transcatheter heart valve medical device player in China – Venus Medtech (Hangzhou) Inc. (“Venus Medtech” or the “Company“, stock code: 2500.HK), today is pleased to announce the appointment of two new cardiovascular experts to its advisory team. Dr. Scott Lim MD and Dr. Chaim Lotan will be joining Venus Medtech’s Global Advisory […]
PREDICT-LAA Trial Enrolls First Patient
GENT, Belgium–(BUSINESS WIRE)–FEops, a leader in personalized predictive planning for structural heart interventions, is proud to announce that today the first patient has been enrolled in the physician-initiated PREDICT-LAA trial. The trial is led by Righshospitalet (Copenhagen, Denmark) and aims to assess whether the use of FEops HEARTguide™ computer simulations based on cardiac CT-imaging can contribute to […]
Stereotaxis to Ring the Opening Bell® of the New York Stock Exchange
ST. LOUIS, Jan. 16, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that David Fischel, Chairman and CEO, will ring the Opening Bell® of the New York Stock Exchange on Tuesday, January 21, 2020 to celebrate Stereotaxis’ positive impact […]
Leading Cardiovascular Researcher And PAD Treatment Pioneer, Dr. Christopher Kevil, To Chair JanOne Scientific Advisory Board
Kevil brings global scientific expertise to advance JanOne’s drug development portfolio and advise on upcoming Phase 2b clinical trials for PAD LAS VEGAS, Jan. 16, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ:JAN) appoints Christopher Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to lead its scientific advisory board. In this role, Dr. Kevil will […]
FDA Grants Fast Track Designation to Arena Pharmaceuticals’ APD418 for Development in Decompensated Heart Failure Patients
– APD418 currently in Phase 1 clinical investigation – data expected this year SAN DIEGO, Jan. 16, 2020 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for APD418, a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, in development for the treatment of […]
Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer™
VANCOUVER, Jan. 15, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced receipt of an Administrative Acceptance […]



